Grünenthal GmbH filed and obtained publication of EP3597182A1, a patent application for an aqueous oral formulation of tapentadol (a potent analgesic). The application claims priority to multiple IPC classifications including A61K 9/08 (aqueous pharmaceutical forms) and A61K 31/137 (tapentadol as active ingredient). The patent names six inventors and designates all 35 EPO contracting states.

Third parties seeking to challenge this patent have a nine-month window from the publication date to file observations or opposition with the EPO. Competitors developing similar tapentadol formulations should review the specific claim language for potential design-around opportunities. This publication does not create compliance obligations but provides notice of potential future market exclusivity.